



May 31, 2024

Notice Regarding Offer of Refunds to 340B Entities

Valinor Pharma, LLC (“Valinor”) has identified a minor discrepancy in its calculation of the Medicaid Best Price for Movantik[®], which resulted in a small variance in the 340B price for the product during Q1 2024 and a portion of Q2 2024, until the corrected 340B price was reported to wholesalers on May 14, 2024. As a result of this minor discrepancy, Valinor has determined that a refund may be owed to 340B Covered Entities that purchased any of the below NDCs during the relevant time period.

Time Period	NDC-11	Product Name
Jan. 1, 2024 – May 13, 2024	82625-8801-01	Movantik 12.5mg 30ct
Jan. 1, 2024 – May 13, 2024	82625-8802-01	Movantik 25mg 30ct
Jan. 1, 2024 – May 13, 2024	82625-8802-03	Movantik 25mg 100ct

This Notice is intended to give affected Covered Entities that may be owed less than \$5.00 an opportunity to request refunds.

Accordingly, if a 340B Covered Entity believes it is owed a refund, the Covered Entity should contact info@valinorrx.com if it wishes to request a refund or has any questions. The Covered Entity may be asked to provide additional information for verification purposes, such as the applicable NDC(s), purchase volume(s) and time period(s). Upon validation that a requested refund is owed, Valinor will approve the refund request.